Journal: Natural Products and Bioprospecting

Article Title: Combined treatment with naringin and osthole ameliorates colitis through microbiota–amino acid metabolism and the JNK pathway

doi: 10.1007/s13659-025-00582-z

Figure Lengend Snippet: Combination therapy of naringin and osthole inhibits inflammatory damage in vitro. A – C CCK-8 detection of cell viability. D Perform RT-qPCR on IL-6, IL-1β, TNF-α, and IL-10 in HT-29 cells. E – G Western blotting and quantitative analysis of apoptosis factors Bcl-2, Bax, and Cleaved-Caspase-3. Data are presented as mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001

Article Snippet: The human colon cancer cell line HT-29 was obtained from the American Type Culture Collection (ATCC, USA) and were cultured in DMEM containing 100 IU/mL penicillin, 100 μg/mL streptomycin, and 10% fetal bovine serum (FBS) in a humidified incubator at 37 °C with 5% CO 2 .

Techniques: In Vitro, CCK-8 Assay, Quantitative RT-PCR, Western Blot

Journal: Natural Products and Bioprospecting

Article Title: Combined treatment with naringin and osthole ameliorates colitis through microbiota–amino acid metabolism and the JNK pathway

doi: 10.1007/s13659-025-00582-z

Figure Lengend Snippet: The combined administration of naringin and osthole alleviates colitis in mice by inhibiting the JNK/NF-κB signaling pathway in vitro and in vivo. A , B Western blot for NF-κB signing pathway in vivo and in vitro. C , D Western blot for JNK signing pathway in vivo and in vitro. E Western blot of JNK signing pathway in vitro after JNK inhibitor (SP600125) treatment. Data are presented as mean ± SEM (n = 3). F RT-qPCR of IL-6, IL-1β, TNF-α and IL-10 in HT-29 cells after pretreatment with JNK inhibitor SP600125. Data are presented as mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001

Article Snippet: The human colon cancer cell line HT-29 was obtained from the American Type Culture Collection (ATCC, USA) and were cultured in DMEM containing 100 IU/mL penicillin, 100 μg/mL streptomycin, and 10% fetal bovine serum (FBS) in a humidified incubator at 37 °C with 5% CO 2 .

Techniques: In Vitro, In Vivo, Western Blot, Quantitative RT-PCR

Journal: bioRxiv

Article Title: Molidustat Targets a Synthetic Lethal Vulnerability in APC-Mutant Colorectal Cancer through GSTP1 and PHD2 Co-Inhibition

doi: 10.64898/2026.01.31.702998

Figure Lengend Snippet: A. Percentage of Cleaved Caspase 3/7 positive HT29 (top), and RKO (bottom) cells. Cells were treated with Molidustat for 48 hours at indicated concentrations, 10uM Staurosporine was used as a positive control (100% cell death). Mean + SEM is assessed by unpaired two tailed Student’s t-test, **p<0.01, (ns) non-significant. B. Representative images of Cleaved Caspase-3/7 signal in DMSO, Molidustat (90 μM), and Staurosporine treated cells. Scale bar: 300 μm. C. Representative Western Blot of PHD2 levels in HT29 cells. D. Percentage confluency of HT29 cells post-transfection with the indicated guide RNAs. E. Cleaved Caspase-3/7 signal in HT29 cells post-transfection with the indicated crRNAs. Mean + SEM is assessed by two-way ANOVA, *p<0.05. N = 3 biologically independent experiments.

Article Snippet: Human colorectal cancer cell lines HT29 and RKO were obtained from the American Type Culture Collection (ATCC) and maintained in Dulbecco’s Modified Eagle Medium (DMEM; Sigma-Aldrich, D6429) supplemented with 10% (v/v) fetal bovine serum (FBS; Gibco, 16000044), 1% (v/v) penicillin-streptomycin (Gibco, 15140122), and 2 mM L-glutamine (Sigma-Aldrich, G7513).

Techniques: Positive Control, Two Tailed Test, Western Blot, Transfection